IMMURON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1 AUD | 0.00% |
|
-9.09% | +29.87% |
| Apr. 10 | Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024 | CI |
| Apr. 10 | Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).
Sector
Pharmaceuticals
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| +29.87% | 14.68M | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -25.01% | 27.69B | |
| +53.61% | 24.28B | |
| -8.15% | 17.09B | |
| -33.74% | 13.67B | |
| -16.96% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
- Stock Market
- Equities
- IMC Stock
- News Immuron Limited
- Immuron : Says IMM124E Product May Offer New Way of Preventing COVID-19 Infection
